Unlocking the Potential of C17orf107: A Potential Drug Target and Biomarker

Target Name: C17orf107

NCBI ID: G100130311

C17orf107

Other Name(s): chromosome 17 open reading frame 107 | Uncharacterized protein C17orf107 | CQ107_HUMAN | Chromosome 17 open reading frame 107

Unlocking the Potential of C17orf107: A Potential Drug Target and Biomarker

C17orf107 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is located in chromosome 17 and has been shown to play a role in various physiological processes, including cell growth, development, and disease. In this article, we will explore the potential implications of C17orf107 as a drug target and biomarker, and discuss the research that has been done in this field to date.

C17orf107 as a Potential Drug Target

C17orf107 has been shown to interact with various protein molecules, including the protein known as FAK. FAK is a protein that is involved in cell-extracellular matrix (ECM) interactions, and has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have shown that C17orf107 can interact with FAK and regulate its activity. This interaction between C17orf107 and FAK has led to the hypothesis that C17orf107 may be a drug target. If this is true, then targeting C17orf107 may be a promising approach for treating diseases that are currently underserved by traditional therapies.

C17orf107 as a Potential Biomarker

In addition to its potential as a drug target, C17orf107 has also been shown to be a potential biomarker. The use of RNA-based assays, such as microarray analysis and RNA sequencing, allows researchers to identify and quantify specific genes that are expressed in a cell or tissue. This can be useful for the discovery of potential biomarkers that can be used to diagnose or predict the outcome of a disease.

Studies have shown that C17orf107 has been expressed in a variety of tissues and cells, including brain, heart, and blood cells. Additionally, it has been shown to be involved in the regulation of cellular processes, such as cell growth, apoptosis, and inflammation. This suggests that C17orf107 may be a useful biomarker for the diagnosis or prediction of certain diseases.

The Potential for C17orf107 as a Drug Target and Biomarker

The potential of C17orf107 as a drug target and biomarker is still being explored, but it is clear that it has the potential to revolutionize the field of medicine. If C17orf107 is indeed a drug target, then targeting it may lead to the development of new treatments for diseases that are currently underserved by traditional therapies. Additionally, if C17orf107 is a biomarker, then it may be used to diagnose or predict the outcome of certain diseases.

Conclusion

In conclusion, C17orf107 is a non-coding RNA molecule that has been shown to interact with various protein molecules, including the protein known as FAK. It has also been shown to be involved in the regulation of cellular processes, such as cell growth, apoptosis, and inflammation. The potential of C17orf107 as a drug target and biomarker is still being explored, but it is clear that it has the potential to revolutionize the field of medicine. Further research is needed to fully understand the potential of C17orf107 and its potential as a drug target and biomarker.

Protein Name: Chromosome 17 Open Reading Frame 107

The "C17orf107 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C17orf107 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets